Please try another search
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Geraldine A. Henwood | 69 | 2019 | President, CEO & Director |
Wayne B. Weisman | 66 | 2019 | Independent Chairman |
Arnold M. Baskies | 74 | 2020 | Independent Director |
Andrew T. Drechsler | 51 | 2020 | Independent Director |
William L. Ashton | 72 | 2019 | Independent Director |
Winston J. Churchill | 83 | 2019 | Independent Director |
Chan Kim Yong | 49 | 2023 | Chief Scientific Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review